Accessibility Menu
Rosetta Genomics logo

Rosetta Genomics(OTC) ROSGQ

Market Cap$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-100%
5 Year-100%
1 Year+0%
1 Month+9,900%
$0.00
+0%
+0.00Today
Rosetta Genomics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-06
Rosetta Genomics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9,900%USD 0.002026-06-22
1 month+9,900%USD 0.002026-06-01
3 month+0%USD 0.002026-04-07
Year to date+9,900%USD 0.002025-12-24
1 year+0%USD 0.002025-07-01
3 year+0%USD 0.002023-06-30
5 year-99.85%USD 0.072021-07-07
Since inception-100%USD 5,270.412007-02-27

Rosetta Genomics Financials at a Glance

Market Cap

$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.49M

Net Income (TTM)

-$14.27M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-22.90 (Low)

Price

$0.00

Volume

326

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Dec 18, 2024

ROSGQ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rosetta Genomics

Rosetta Genomics Ltd. is a global leader in genomic diagnostics, specializing in innovative microRNA technologies. The company offers a diverse range of diagnostic assays aimed at improving patient care in oncology and other medical fields.

Products and Services
  • RosettaGX Cancer Origin for identifying metastatic cancer sources
  • mi-KIDNEY for classifying kidney tumors from pathology samples
  • UroVysion, a urine-based FISH assay for bladder cancer detection
Growth Outlook
  • Collaborative partnership with Meir Medical Center to develop microRNA classifiers
  • Expansion of diagnostic offerings in oncology and urology markets
  • Potential for increased adoption of microRNA technologies in clinical settings
Financial Highlights
  • Recent quarterly revenue of $870,000, showing growth potential
  • Cash and short-term investments totaling $1,325,000, providing operational liquidity
  • Current ratio of 2.50 indicates strong short-term financial health
Rosetta Genomics Ltd. focuses on advancing genomic diagnostics through its proprietary technologies. The company’s product portfolio includes various assays that assist healthcare professionals in diagnosing and treating cancer more effectively. With a strong emphasis on research and development, Rosetta Genomics is positioned to capitalize on the growing demand for innovative diagnostic solutions. The recent partnership with Meir Medical Center highlights the company's commitment to expanding its capabilities in the oncology space. Financially, the company has demonstrated resilience with a solid cash position and a favorable current ratio, suggesting a stable foundation for future growth.
AI Generated • Jul 1, 2026

Industry

Biotechnology

Headquarters

Rehovot, TA 76706, IL

ROSGQ Financials

Key Financial Metrics (TTM)

Gross Margin

19.44%

Operating Margin

-169.63%

Net Income Margin

-175.80%

Return on Equity

-135.07%

Return on Capital

-190.75%

Return on Assets

-135.72%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

5.93M

Volume

326

Avg. Volume

231.758

Financials (TTM)

Gross Profit

$636.00K

Operating Income

-$12.90M

EBITDA

-$13.46M

Operating Cash Flow

-$20.03M

Capital Expenditure

$0.00

Free Cash Flow

-$21.04M

Cash & ST Invst.

$1.33M

Total Debt

$2.45M

Rosetta Genomics Performance Analysis

Rosetta Genomics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22016-06-30-84.5%
Q32016-09-30444.6%
Q42016-12-31-8.2%
Q22017-06-30N/A
Rosetta Genomics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22016-06-3018.8%
Q32016-09-30-16.9%
Q42016-12-31-21.9%
Q22017-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2017YOY CHG

Revenue

$870.00K

-66.6%

Gross Profit

$301.00K

-68.1%

Gross Margin

34.60%

N/A

Market Cap

$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.98

N/A

Employees

86

N/A

Net Income

-$2.07M

+48.7%

EBITDA

-$1.37M

+65.8%

Quarterly Fundamentals

Name
Q2 2017YOY CHG

Total Cash

$1.33M

-88.9%

Total Debt

$2.45M

N/A

Accounts Receivable

$987.00K

-74.1%

Inventory

$0.00

N/A

Long Term Debt

$2.43M

N/A

Short Term Debt

$110.00K

N/A

Return on Assets

-1.36%

N/A

Return on Invested Capital

-1.92%

N/A

Free Cash Flow

-$12.26M

N/A

Operating Cash Flow

-$11.96M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ONCSQOncoSec Medical Incorporated
$0.00+0.00%
SIGOSunset Island Group, Inc.
$0.00+0.00%
MOTSMotus GI Holdings, Inc.
$0.00+0.00%
LGBICannabiz Mobile, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About ROSGQ

What is the current price of Rosetta Genomics?

Rosetta Genomics is trading at $0.00 per share.

What is the 52-week range for Rosetta Genomics?

Over the past 52 weeks, Rosetta Genomics has traded between $0.00 and $0.00.

How much debt does Rosetta Genomics have?

Rosetta Genomics total debt is unavailable.

How much cash does Rosetta Genomics have on hand?

Rosetta Genomics does not have cash on hand data available.

What is Rosetta Genomics’s dividend yield?

Rosetta Genomics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.